for Tardive Dyskinesia in Adults

Know more
AS YOU GO

Use the personalized Appointment Preparation Guide to have a conversation with your healthcare provider about what you're experiencing.

Eligible patients may pay as little as $ As little as 0 dollars per month. per month
Discover the benefits

Offer is only available to patients with commercial insurance. Offer is NOT available to patients eligible for Medicare, Medicaid, or any other government payer coverage. Out-of-pocket costs may vary. Exclusions and limitations apply. Please see complete Terms and Conditions.

References:

1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

2. Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595-604.

3. Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y). 2013;3:tre-03-161-4138-1.

4. Warikoo N, Schwartz TL, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Nova Science Publishers, Inc.; 2013:235-258.

5.  Derrow P. What is tardive dyskinesia? Symptoms, causes, diagnosis, treatment, and prevention. Everyday Health. Accessed January 24, 2024. https://www.everydayhealth.com/tardive-dyskinesia/

6. Jackson R, Brams MN, Citrome L, et al. Assessment of the impact of tardive dyskinesia in clinical practice: consensus panel recommendations. Neuropsychiatr Dis Treat. 2021;17:1589-1597.